Dr David Thomson
David Thomson qualified from Oxford University Medical School in 2004 with a First Class honours degree. During his postgraduate medical training he undertook a research Fellowship at the University of Manchester with attachment to the University of Pennsylvania, and was awarded a Doctor of Medicine (MD) higher research degree in 2015. He also has an interest in medical education and completed a Postgraduate Certificate in Medical Education with Distinction (Edge Hill University, 2014). Dr Thomson was appointed Consultant Clinical Oncologist at The Christie (2015) and Honorary Senior Lecturer at The University of Manchester, specialising in the treatment of head and neck cancer.
As the Clinical Director of the Greater Manchester Head and Neck Cancer Pathway Board, he is passionate about improving the survival outcomes and long-term quality of life for patients. Dr Thomson is actively involved in clinical research and is Chief Investigator for the UK phase 3 NIMRAD trial (assessing the benefit of hypoxia modification using nimorazole with radiotherapy for head and neck cancer), Chief Investigator for the UK phase 3 TORPEdO trial (assessing benefit of proton beam therapy to reduce side effects in the treatment of oropharyngeal cancer), and Principal Investigator for a number of NCRI portfolio studies. He is Proton Beam Therapy National Policy Lead and National Panel Member for Head and Neck Cancer. Dr Thomson is also the clinical lead for the implementation of electronic patient reported outcomes in head and neck cancer at The Christie.
Claire has been working at GM Cancer for over three years as a pathway manager, facilitating five pathway boards to deliver system wide improvements to cancer pathways and patient care, including Breast, Head and Neck, Genomics, Neuro-oncology and Hepato-Pancreato-Biliary. The boards offer an objective and collaborative approach to service improvement and bring together stakeholders from across Greater Manchester to create an engaged, multidisciplinary board which is representative of the whole patient pathway.
Prior to working at GM Cancer, Claire worked at Cancer Research UK as their Northwest Clinical Research Associate, covering a range of early phase clinical trials. Claire has also held roles at The Christie Clinical Trials Unit and Macmillan building a wealth of experience in clinical cancer research and service improvement.
Claire has also qualified as a coach and mentor with the Chartered Management Institute and supports colleagues within The Christie Leadership Framework and leadership of the GM Cancer administrative function.